Surgical Innovation

LivaNova Board Appoints J. Christopher Barry as New Director

Retrieved on: 
Friday, October 6, 2023
Medical Devices, Surgery, Hospitals, Clinical Trials, Health Technology, Cardiology, Other Health, Biotechnology, General Health, Health, Surgical Innovation, Medtronic, Senior, Retirement, Texas Tech University, Audit, LivaNova, Interim, LIVN, Growth, Marketing, PLC, Environmental science, NuVasive, Covidien, Patient, Pension fund, Management

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.
  • Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board on December 31, 2023.
  • “The LivaNova Board of Directors is pleased to welcome Chris Barry,” said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova.
  • With these changes, the LivaNova Board will be comprised of 10 Directors until Saia’s retirement at the end of the year.

City of Hope Opens First U.S. Multicenter Clinical Trial for Robotic Single-Port Mastectomies for Breast Cancer Patients

Retrieved on: 
Tuesday, October 3, 2023
Technology, Health, Women, Oncology, Robotics, Health Technology, Research, Surgery, Consumer, Science, Clinical Trials, Surgical oncology, City of Hope, Surgeon, Clinical trial, Cancer, Lead, Food and Drug Administration Amendments Act of 2007, Urology, Patient, Surgical Innovation, Food, Intuition, Breast cancer, Birth control, City, Hope

City of Hope, one of the largest cancer research and treatment organizations in the United States, is opening a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, is opening a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies.
  • “City of Hope is once again taking the lead in investigating innovations, treatments and therapies that are making big leaps forward for patients with cancer.
  • “City of Hope offers the most advanced breast cancer treatments,” said Jamie Rand , M.D., a breast cancer surgeon at City of Hope and subinvestigator on the clinical trial.
  • Surgeons at City of Hope, a leader in robotic surgery , have performed more than 16,000 nonmastectomy robotic procedures.

Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development

Retrieved on: 
Wednesday, September 6, 2023
Prostate Cancer Foundation, Surgical oncology, Royal college, Society, Immunoconjugate, Therapy, Prostate cancer, PSMA, Convergent, Drug, Bayer, Cancer, Radiopharmaceutical, Triplet, Eisai, Surgical Innovation, MD, Patient, Gemini, Weill Cornell Medicine, CFO, Growth, Merrimack Pharmaceuticals, Pharmaceutical industry

These appointments follow the company's recent closing of a $90 million Series A financing round to develop radiopharmaceuticals to treat cancer.

Key Points: 
  • These appointments follow the company's recent closing of a $90 million Series A financing round to develop radiopharmaceuticals to treat cancer.
  • "With our strong financial backing, we are poised to accelerate the clinical development of our lead asset CONV01-a to transform the lives of patients suffering with prostate cancer."
  • Over the past 25 years, Dr. Bander pioneered the development of PSMA-targeted imaging agents and therapeutics, transforming the prostate cancer landscape.
  • Dr. Voliotis is joining Convergent from Zentalis Pharmaceuticals, where he was Senior Vice President & Head of Global Development.

Lauded Neurosurgeon, Researcher and Inventor Nicholas Theodore, MD Joins Harvard MedTech’s Medical Advisory Board

Retrieved on: 
Tuesday, January 10, 2023
Mental Health, Medical Devices, Health, Surgery, Research, Science, Brain, Algorithm, Metabolic pathway, Mike Donlin, Depression, Johns Hopkins, Anxiety, Barrow Neurological Institute, DARPA, Defense, MD, Department of Defense Serum Repository, Harvard University, Johns Hopkins School of Medicine, Spine, Patient, Research, FACS, Neurosurgery, Carnegie Center for Art & History, Surgical Innovation, Pain management, Medtech, Pain, Pharmaceutical industry, Medical device, Medical imaging

Nationally recognized neurosurgeon Nicholas Theodore, MS, MD, FAANS, FACS has accepted an invitation to join the Medical Advisory Board of Harvard MedTech , announced Gerry Stanley, M.D., Chief Medical Officer at Harvard MedTech.

Key Points: 
  • Nationally recognized neurosurgeon Nicholas Theodore, MS, MD, FAANS, FACS has accepted an invitation to join the Medical Advisory Board of Harvard MedTech , announced Gerry Stanley, M.D., Chief Medical Officer at Harvard MedTech.
  • Theodore is the Director of the Neurosurgical Spine Program at the most prestigious neurosurgical program in the country,” noted Dr. Stanley.
  • “In addition to his surgical innovations and research endeavors, Dr. Theodore holds over 20 patents for medical devices and procedures.
  • The purpose of the Harvard MedTech Medical Advisory Board is to facilitate industry-wide adoption of Vx® Therapy in the treatment of workplace trauma.

Healthcare Venture Fund Wavemaker Three-Sixty Health Announces New Venture Partner Monica Jain, M.D.

Retrieved on: 
Tuesday, April 12, 2022
Biotechnology, General Health, Finance, Health, Professional Services, Family, Medicine, Adoption, Committee, Association, Boston University School of Public Health, Cedars-Sinai Medical Center, Boston University, CA, AUM, Leadership, Biomedicine, Boston University School of Medicine, Education, Business, Executive Committee, General partnership, LinkedIn, Growth, LP record, Love, Technology, WaveMaker, Public Committee Against Torture in Israel, Society, Education Committee, Association of Women Surgeons, Committee of Chiefs of Military Medical Services in NATO, American College, Surgical Innovation, American Association of Endocrine Surgeons, Multimedia, Industry, Biomedical engineering, University, Association for Academic Surgery, Bessemer Venture Partners, Pharmaceutical industry, Dentistry, Medical device, Health insurance, Science

Wavemaker Three-Sixty Health (Wavemaker 360), the nations leading venture fund focused singularly on early-stage (primarily seed) healthcare disruptors, welcomes Monica Jain, M.D.

Key Points: 
  • Wavemaker Three-Sixty Health (Wavemaker 360), the nations leading venture fund focused singularly on early-stage (primarily seed) healthcare disruptors, welcomes Monica Jain, M.D.
  • The country and healthcare industry are addressing significant challenges such as pandemic recovery, hospital at home, and the substantial staff shortages.
  • Dr. Jain comes to Wavemaker 360 as a multidisciplinary healthcare expert between her current role at Cedars-Sinai and her background in biomedical engineering and healthcare innovation.
  • Wavemaker Three-Sixty Health (Wavemaker 360) is the nations leading venture fund focused singularly on early-stage (primarily seed) healthcare disruptors in the areas of health-tech, digital health, medical device, telehealth, pharma-tech, science and marketplaces.

Medtronic announces first procedure in Europe with Hugo™ robotic-assisted surgery system

Retrieved on: 
Wednesday, February 2, 2022
Diagnosis, Patient, OLV, Sale, Health, Physician, Sofie (surgical robot), Twitter, Mazor, Research, Adoption, Bed, RAS, Surgical Innovation, Partnership, Program, Disease, CE, U.S. Securities and Exchange Commission, Goldfarb, Surgeon, Pain, Heart, Security (finance), NYSE, LinkedIn, Aftercare, Solution, Hospital, Hugo, Data analysis, Healthcare, Dentistry, Medical device, Medtronic, EU

DUBLIN and AALST, Belgium, Feb. 2, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and OLV Hospital Aalst today announced that the first clinical procedure in Europe was performed with the Hugo™ robotic-assisted surgery (RAS) system. The robotic prostatectomy was performed by Prof. Alexandre Mottrie, M.D., head of urology at OLV Hospital in Aalst, Belgium, and chief executive officer and founder of the Belgium-based ORSI Academy, a multidisciplinary center for training, research and development, and data analysis to improve minimally invasive surgery best practices.

Key Points: 
  • "Performing Europe's very first procedure with the Hugo RAS system is a career highlight for me," said Dr. Mottrie.
  • In 2021, Medtronic announced the first urologic and gynecologic procedures with the Hugo system in Latin America and Asia-Pacific.
  • Those procedures and cases in Europe will become part ofthe Hugo RAS system patient registry, which is collecting clinical data to support regulatory submissions around the world.
  • "The Hugo RAS system introduces the long-awaited power of choice in the category and will redefine all that robotic-assisted surgery can make possible," said Henk Westendorp, senior country director Benelux at Medtronic.

Medtronic Hugo™ robotic-assisted surgery system receives Health Canada licence, further enabling access to robotic-assisted surgery in Canada

Retrieved on: 
Tuesday, December 7, 2021
U.S. Securities and Exchange Commission, Engineering, NYSE, Health, Surgical Innovation, Disease, Pain, Sofie (surgical robot), RAS, Patient, Asia, Canadian Institute for Health Information, Hugo, Urology, CE, CE marking, Goldfarb, Heel, Diagnosis, Sale, Solution, Health Canada, Dentistry, Health insurance, Medical device

It can help optimize our precious healthcare human resources when patients spend less time in and out of the hospital, " said Neil Fraser, president of Medtronic Canada.

Key Points: 
  • It can help optimize our precious healthcare human resources when patients spend less time in and out of the hospital, " said Neil Fraser, president of Medtronic Canada.
  • In Canada, the Hugo RAS system has a Health Canada licence.
  • In the U.S., the Hugo RAS system is an investigational device not for sale.
  • Touch Surgery Enterprise is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition.

Yuman Fong, M.D., City of Hope’s Chair in Surgical Oncology, Elected to National Academy of Medicine

Retrieved on: 
Monday, October 18, 2021
Science, Biotechnology, Research, Surgery, Oncology, Health, Hospitals, Genetics, Instagram, Surgical Innovation, National Academies of Sciences, Engineering, and Medicine, Health equity, Bile, History, Diabetes, Technology, Center, National Cancer Institute, NAM, Surgical oncology, Solution, Liver, City of Hope National Medical Center, Translational Genomics Research Institute, Gallbladder, Biomedical Research, U.S. News & World Report, Cancer, National Academy of Medicine, City, News, National Comprehensive Cancer Network, American Surgical Association, YouTube, PLOS Biology, Multimedia, CAR, Health, Pancreas, National academy, Science, Caligiuri, Public health, Haematopoietic system, Virus, Immunotherapy, Twitter, City of Hope, Research, Biology, Robotics, NCI, Pharmaceutical industry

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The National Academy of Medicine (NAM) honored Fong for transforming the fields of liver surgery, robotics in surgery, imaging and display in medicine, and gene therapy.
  • Fong has been a surgical oncologist at City of Hope since 2014 and serves as director of its Center for Surgical Innovation, director of its Center for International Medicine, and chair and professor of its Department of Surgery.
  • Founded in 1970, NAM is one of the three academies that make up the National Academies of Sciences, Engineering, and Medicine .
  • He is also City of Hopes Deana and Steve Campbell Physician-in-Chief Distinguished Chair.

Ohio State University Wexner Medical Center Receives Ohio's First Hyperfine Portable MRI Systems to Speed Scanning and Diagnosis for Urgent Brain Injuries

Retrieved on: 
Thursday, September 16, 2021
Ohio State University Wexner Medical Center, Income, Food, Stroke, Hyperfine structure, FDA, Technology, University, Surgical Innovation, Ohio State University, SITL, Yale New Haven Hospital, University of California, Irvine Medical Center, Doctor of Philosophy, Emergency department, Patient, Apple, MRI, Champaign County, Illinois, Emergency, Map, Brain, Food and Drug Administration, Physician, Solution, COVID-19, ADC, DWI, FLAIR, IPad, COVID, Magnetic resonance imaging, Hospital, Nursing, Parent, Medical imaging

The Ohio State Wexner Medical Center is the first in the state of Ohio, and one of the first in the country, to offer this technology to its patients.

Key Points: 
  • The Ohio State Wexner Medical Center is the first in the state of Ohio, and one of the first in the country, to offer this technology to its patients.
  • "As one of the leading comprehensive stroke centers in the country, Ohio State Wexner Medical Center has always been on the cutting edge of diagnosing and treating critical brain injuries," said Rob Korn, senior vice president of sales for Hyperfine.
  • "We're excited to provide Ohio State with the world's first portable MRI system which gives clinicians critical decision-making capabilities across a variety of clinical settings."
  • Hyperfine designed the Swoop Portable MR Imaging System to overcome patient transport and dedicated room requirements associated with fixed conventional MRI systems.

Medtronic Announces NAVABLATE Study Results Released in Late-Breaking Podium Presentation at European Respiratory Society International Congress 2021

Retrieved on: 
Tuesday, September 7, 2021

DUBLIN, Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new clinical data from the NAVABLATE study, which highlights the much anticipated safety and performance results on microwave ablation used bronchoscopically with the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology in conjunction with the Medtronic electromagnetic navigation bronchoscopy system. Results were reported as a late-breaking presentation at the virtual European Respiratory Society International Congress 2021, September 5, 2021.

Key Points: 
  • Results were reported as a late-breaking presentation at the virtual European Respiratory Society International Congress 2021, September 5, 2021.
  • NAVABLATE is a prospective, multi-center study that enrolled 30 subjects in the United Kingdom and Hong Kong to characterize the safety and performance of the CE Marked Emprint Ablation Catheter Kit.
  • All patients underwent a bronchoscopic ablation procedure using the Emprint Ablation Catheter Kit and were followed for one month post procedure.
  • The composite rate of adverse events related to the Emprint Ablation Catheter Kit was 3.3% (one subject with mild hemoptysis).